Patients undergoing haematopoietic cell transplantation face a gruelling path to recovery. Before receiving healthy stem cells, they must endure intensive conditioning regimens—high-dose chemotherapy or radiation therapy designed to eradicate diseased cells and suppress the immune system. While these preparatory treatments are essential for transplant success, they carry a heavy toll of collateral damage. One of the most painful and clinically challenging complications of this process is oral mucositis, a condition characterised by severe inflammation, ulceration, and breakdown of the mucosal lining in the mouth.
For these patients, the simple act of swallowing, speaking, or drinking water can become an agonising ordeal. Beyond the immediate physical suffering, severe oral mucositis introduces major clinical risks. Deep mucosal ulcers serve as open gateways for opportunistic pathogens, threatening vulnerable, immunocompromised patients with life-threatening systemic infections. It frequently necessitates the use of strong intravenous painkillers, forces the introduction of artificial nutritional support, and extends hospital stays, significantly driving up the overall cost of care. Despite its prevalence, clinical teams have long struggled to find highly effective, cheap, and easily tolerated preventative therapies to shield patients from this debilitating mucosal damage.
The clinical challenge of mucosal toxicity
The biological cascade leading to oral mucositis begins almost immediately after the initiation of conditioning therapy. The rapid cell turnover that characterised a healthy oral mucosa makes it highly susceptible to the toxic effects of chemotherapy and radiation. As the mucosal cells die off and the tissue’s ability to regenerate is compromised, a complex pathway of oxidative stress and inflammatory signalling is triggered, culminating in painful tissue ulceration.
In the context of haematopoietic cell transplantation, the risk is particularly acute. Patients undergoing myeloablative conditioning—the most intense form of preparatory therapy—experience profound mucosal destruction. Similarly, those receiving allogeneic transplants (cells from a donor) rather than autologous transplants (their own stored cells) are at an elevated risk of severe complications.
To address this, clinical researchers have explored various protective agents, ranging from basic saline rinses to advanced growth factors. However, many existing interventions are either expensive, difficult to administer, or come with their own suite of side effects. This has left a critical gap in supportive care: the need for an accessible, low-cost agent that can be easily integrated into standard transplant protocols to protect the oral cavity.
Testing N-acetylcysteine as a preventive rinse
A clinical trial has recently evaluated whether N-acetylcysteine, a widely available and inexpensive compound, could serve as an effective preventative mouthwash. Traditionally used as a mucolytic agent to clear mucus in respiratory conditions and as an antidote for paracetamol poisoning, N-acetylcysteine possesses well-documented antioxidant and anti-inflammatory properties. These biological mechanisms make it a logical candidate for countering the oxidative stress and tissue damage that drive oral mucositis.
The study was designed as a single-centre, double-blind, randomised, placebo-controlled trial. It enrolled 106 adult patients who were undergoing either autologous or allogeneic haematopoietic cell transplantation. The participants were randomly allocated in a one-to-one ratio into two distinct arms: 54 patients received the active N-acetylcysteine mouthwash, while 52 patients received a matching placebo rinse.
The treatment protocol was highly structured. Patients in the active group used a mouthwash containing 600 milligrams of N-acetylcysteine every six hours, amounting to a total daily dose of 2400 milligrams. This regimen commenced on the very first day of their conditioning therapy and continued either until 14 days after their transplant or until neutrophil engraftment occurred—whichever of these milestones was reached first. To ensure objective evaluation, clinical staff assessed the patients’ oral cavities daily using the standard World Health Organization Oral Toxicity Scale. This scale categorises the severity of mucositis from mild soreness to severe, life-threatening ulceration that prevents any oral intake.
A dramatic reduction in severe complications
The primary objectives of the trial were to assess the overall incidence of oral mucositis and, crucially, the incidence of severe oral mucositis, which corresponds to grades 3 and 4 on the World Health Organization scale. The findings revealed a nuanced but highly significant clinical impact.
When looking at the overall occurrence of oral mucositis of any grade, the difference between the two groups did not reach statistical significance. In the N-acetylcysteine group, 61.1 per cent of patients (33 out of 54) developed some form of oral mucositis, compared to 73.1 per cent (38 out of 52) in the placebo group. While there was a numerical reduction in the active treatment group, the statistical analysis (P = 0.190) showed that the mouthwash did not reliably prevent the onset of mild or moderate mucosal irritation.
However, the results for severe oral mucositis—the clinically consequential stage that causes the most profound suffering and complications—were striking. Only 5.6 per cent of patients (3 out of 54) in the N-acetylcysteine group progressed to severe, grade 3 or 4 mucositis. In stark contrast, 25.0 per cent of patients (13 out of 52) in the placebo group suffered from these severe forms. This difference was highly statistically significant (P = 0.006). Furthermore, the overall distribution of mucositis severity grades across the entire study population significantly favoured the N-acetylcysteine group (P = 0.046), proving that the rinse successfully halted the progression of the condition to its most debilitating stages.
The trial also demonstrated that the mouthwash was exceptionally well tolerated. The active rinse did not cause significant distress or adverse reactions; any reported gastrointestinal side effects were mild and occurred infrequently. This high level of tolerability is vital for transplant patients, who are already dealing with nausea, loss of appetite, and general malaise.
To better understand the variables influencing these outcomes, the researchers performed a multivariable analysis. This analysis confirmed that several factors were strongly associated with higher odds of developing oral mucositis. These included undergoing an allogeneic transplant, receiving a highly intense myeloablative conditioning regimen, displaying suboptimal adherence to the mouthwash schedule, and being assigned to the placebo group. The finding regarding adherence underscores the practical necessity of patient compliance in achieving the protective benefits of the therapy.
Boundaries and future pathways
While these results are highly encouraging for supportive oncology, the trial has clear limitations that must be acknowledged before the intervention can be widely adopted. As a single-centre study, the findings reflect the specific patient demographics, nursing care, and conditioning protocols of one institution. Whether the same impressive reduction in severe mucositis can be replicated across diverse hospital settings remains to be seen.
Additionally, the study did not show that N-acetylcysteine can prevent the initial onset of mild mucosal inflammation. Patients and clinicians must understand that the mouthwash is not a complete shield against all oral discomfort, but rather a tool to prevent mild irritation from degenerating into severe, ulcerated disease.
To transition this intervention into standard clinical practice, the researchers emphasise that multicentre trials are an essential next step. These future studies will need to employ standardised, stable formulations of the mouthwash to ensure consistent dosing and chemical stability. Moreover, incorporating patient-reported outcomes—such as direct pain scores and subjective ease of swallowing—will be critical to fully understanding the therapy’s impact on patient well-being and clinical recovery.
Sources
- N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial, Tahmasebi M et al., Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026-10-04
- Publisher record (DOI)
The R&D takeaway
For organisations funding and planning clinical research, this trial highlights the immense strategic value of repurposing cheap, well-characterised compounds to solve high-impact clinical challenges in supportive care. Rather than focusing solely on absolute prevention, R&D programs can achieve highly valuable clinical and commercial endpoints by targeting the reduction of symptom severity. To successfully scale such low-cost interventions, future funding should prioritise the development of standardised, stable formulations and the integration of patient-reported metrics in multi-institutional validation trials.
The R&D Innovate desk